image descriptionimage description

7-8 out of 10 people on HUMIRA can expect a reduction in skin symptoms after just four months3,4

Is your moderate to severe chronic plaque psoriasis impacting the way you live?

Having raised, inflamed, red lesions that are covered by silvery /white scales doesn’t have to be the way. If topical treatments are not enough there are other treatments that have been proven effective in treating moderate to severe chronic plaque psoriasis such as;

  • phototherapy treatments
  • systemic treatments (like methotrexate and retinoids, biologics such as HUMIRA).

HUMIRA has been proven to be effective for the treatment of moderate to severe chronic plaque psoriasis

HUMIRA treatment is only available on prescription, so if you have moderate to severe chronic plaque psoriasis and are still experiencing symptoms despite your current treatment, you may want to talk to a dermatologist to see if HUMIRA is right for you.

The government medicine funding agency, PHARMAC, fully subsidises HUMIRA if your psoriasis has not fully responded to other medicines prescribed by a specialist, and you meet other criteria required by PHARMAC. Your specialist will discuss whether HUMIRA is right for you, and whether you may qualify for PHARMAC funded treatment.

HUMIRA helps to treat moderate to severe chronic plaque psoriasis3,4

Based on clinical trials in adults treated with HUMIRA, it is expected that skin symptoms may improve in 70% to 80% of people after 4 months, and in some patients as early as 2 weeks.3,4

HUMIRA for moderate to severe chronic plaque psoriasis

In New Zealand, dermatologists have been able to prescribe HUMIRA since 2007 so there is over seven years’ experience in New Zealand with prescribing HUMIRA for moderate to severe psoriasis.

References:
# All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.

  1. Revicki D et al. Br J Dermatol. 2008; 158: 549–57
  2. Revicki D et al. J Dermatol Treat. 2007; 18: 341–50
  3. Saurat J H, et al. Br J Dermatol 2008;158:558-66
  4. Menter, A et al. J Am Acad Dermatol 2008;58:106-15

NZ-HUM-0121 TAPS PP9594 Prepared May 2017

Learn how HUMIRA works.

Watch this short video to get a better understanding of how HUMIRA targets and helps to block TNF.

How HUMIRA treatment works video transcript

Usually, your immune system defends your body from many of the things that can harm it. But when the system doesn’t work right, it can attack healthy tissues and organs. This is an autoimmune disease. One part of your immune system is a protein called TNF, which is produced naturally by the body’s immune system. But in certain autoimmune diseases, some people produce too much TNF. This often leads to inflammation. HUMIRA is a medication called a TNF blocker. It works by binding to TNF molecules and blocking them from attaching to and making cells behave in a way which leads to effects on health. In this way, HUMIRA helps reduce the damaging effects of excess TNF. Remember, although HUMIRA can’t stop your body’s overproduction of TNF it can reduce its effects.

The immune system can overproduce the TNF protein, which is one source of inflammation that contributes to the symptoms of psoriasis. HUMIRA targets and helps block TNF (a particular protein), reducing its inflammatory effects and the symptoms of raised, inflamed, red lesions covered by silvery white scales.

Talk to your dermatologist about whether HUMIRA is right for treating your chronic plaque psoriasis

References:
# All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.

  1. Revicki D et al. Br J Dermatol. 2008; 158: 549–57
  2. Revicki D et al. J Dermatol Treat. 2007; 18: 341–50

NZ-HUM-0121 TAPS PP9594 Prepared May 2017

Getting results with HUMIRA for moderate to severe severe chronic plaque psoriasis

HUMIRA may lead to initial improvements in your skin symptoms over a four month period, with some people beginning to respond within four weeks.3,4  Treatment is generally long term and your dermatologist will discuss how long you may need to take HUMIRA.

Start out on the right path by learning how to take HUMIRA correctly

The usual recommended dose for treating moderate to severe chronic plaque psoriasis in adults is an initial dose of 80mg followed by 40mg every two weeks starting one week after the initial dose. Your dermatologist will decide what dosage of HUMIRA you require and how often you need to administer the injection. Only inject as prescribed by them.

HUMIRA treatment is given by injection just under the skin. HUMIRA is available in either a pre-filled single use syringe, or pre-filled single-use auto-injector pen and both come pre-loaded with the exact dose of medicine inside, so it comes ready to inject and you can do it by yourself. Your dermatologist or nurse will be able to help you and be with you for your first injection however before long you will be able to do it by yourself, or if not, it can be given by another healthcare professional or a family member or friend after they have been trained to give injections. Also, for people on HUMIRA in New Zealand you can join the AbbVie Care support programme with access to a nurse to help you.

Watch these short videos to get a better understanding of how to inject HUMIRA.

Pen video also available in the following languages:
Hindi    Simplified Chinese    Samoan    Tongan

NZ-IMM-0046

Syringe video also available in the following languages:    
Hindi    Simplified Chinese    Samoan    Tongan

NZ-IMM-0047

Storage and travelling with HUMIRA

Keep HUMIRA in the outer carton until it is time to use it. HUMIRA must be kept in the refrigerator (+2° C to +8° C) but don’t allow it to freeze. If you are travelling the HUMIRA pre-filled pen or pre-filled syringe may be stored at room temperature (below +25° C) for a maximum period of 14 days, but it must be protected from light. Once removed from the refrigerator for room temperature storage, the syringe or pen must be used within 14 days or discarded even if it is returned to the refrigerator. If additional syringes or pens are being carried, they should be refrigerated (kept between 2°C–8°C).

Join AbbVie Care to receive an ice pack and order a travel wallet through www.abbviecare.co.nz or call 0800 848 243.

When planning to travel overseas it is important that you:

  • talk to your doctor about travelling with HUMIRA
  • carry a letter from your doctor detailing what HUMIRA is, how much you will be taking, and stating that it is for your own personal use
  • leave HUMIRA in its original packaging so it is clearly labeled with your name and dosage instructions (if you are taking HUMIRA pens/syringes with you)

AbbVie Care Support Programme helps take care of you

AbbVie Care is available to you when you are taking HUMIRA. Support from AbbVie Care is designed to complement the care you receive from your specialist and clinic nurse.
AbbVie Care provides personalised support to meet each person’s needs. The aim is by working together people can achieve better outcomes with their health and quality of life.

It’s easy to ENROL

JOIN AbbVie Care to get the best out of your HUMIRA treatment
• Go online to www.abbviecare.co.nz
• Call 0800 848 243

How AbbVie Care supports you:

AbbVie Care Nurse

AbbVie Care Nurse Support

– Home visits or phone calls to help with injecting^
– Scheduled phone calls to provide information and support
– An 0800 number to call when you have a question

www.abbviecare.co.nz

www.AbbVieCare.co.nz

– Helpful resources and tools (ie. travel advice)
– The ability to order your sharps container and travel wallet online
– Medication and appointment reminders
– Visit www.abbviecare.co.nz

AbbvieCare_online-com

Online Community

– Connecting you to others on HUMIRA
– Contact with your AbbVie Care Nurse

AbbvieCare Sharps Disposal Programme

Sharps Disposal Programme

– Delivery of sharps container to safely dispose of your HUMIRA pens and syringes
– Access to pharmacy disposal of your sharps container

AbbvieCare Travel Wallet

Travel Wallet

– Designed to make travelling with HUMIRA safer and easier

Abbvie_Care_Welcome_Kit

Welcome Kit

– Information on all you need to know to get the best out of AbbVie Care
– Ice pack to assist with injecting


References:
All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.
*Home visits do not cover all of New Zealand. Your AbbVie Care Nurse will be able to discuss this with you when you join AbbVie Care.

  1. Revicki D et al. Br J Dermatol. 2008; 158: 549–57
  2. Revicki D et al. J Dermatol Treat. 2007; 18: 341–50
  3. Saurat J H, et al. Br J Dermatol 2008;158:558-66
  4. Menter, A et al. J Am Acad Dermatol 2008;58:106-15

NZ-HUM-0121 TAPS PP9594 Prepared May 2017

The following resources have been compiled to help you get support outside the HUMIRA Viva programme. We hope you find them useful.

mypsi

My Psoriasis

A New Zealand website provided by AbbVie which provides you with information about life with Psoriasis

www.mypsoriasis.co.nz

Psoriasis and Psoriatic Arthritis New Zealand Facebook

The Psoriasis and Psoriatic Arthritis NZ Facebook Group is a community for people with Psoriasis and Psoriatic Arthritis. The group welcomes new members to connect, share stories and tips and support one another.

Psoriasis and Psoriatic Arthritis New Zealand Facebook

Psoriasis Association (Southland)Psoriasis Association Southland

Main support network for people in New Zealand affected by psoriasis and psoriasis-related conditions.

www.psoriasis.org.nz

dermnet

DermNet New Zealand Trust

DermNet NZ provides authoritative information about skin diseases, conditions and treatment for patients and their health professionals.

Go to DermNet website

National Psoriasis Foundation (USA)

Working to find a cure for psoriasis and psoriatic arthritis and to eliminate their devastating effects through research, advocacy and education.

Go to the National Psoriasis Foundation website

References:
# All experiences, possible outcomes or improvements are hypothetical and based on significant Quality Of Life (QOL) improvements as measured in the listed clinical studies. Use of these references does not imply endorsement or approval by any individual or the authors.

  1. Revicki D et al. Br J Dermatol. 2008; 158: 549–57
  2. Revicki D et al. J Dermatol Treat. 2007; 18: 341–50
  3. Saurat J H, et al. Br J Dermatol 2008;158:558-66
  4. Menter, A et al. J Am Acad Dermatol 2008;58:106-15

NZ-HUM-0121 TAPS PP9594 Prepared May 2017